> Detailanzeige

Shickh, Salma; Oldfield, Leslie E; Clausen, Marc; Mighton, Chloe; Sebastian, Agnes; Calvo, Alessia; Baxter, Nancy N; Dawson, Lesa; Penney, Lynette S; Foulkes, William; Basik, Mark; Sun, Sophie; Schrader, Kasmintan A; Regier, Dean A; Karsan, Aly; Pollett, Aaron; Pugh, Trevor J; Kim, Raymond H; Bombard, Yvonne; Pugh, Trevor J; Kim, Raymond H; Bombard, Yvonne; Aguilar-Mahecha, Adriana; Aronson, Melyssa; [...]

“Game Changer”: Health Professionals’ Views on the Clinical Utility of Circulating Tumor DNA Testing in Hereditary Cancer Syndrome Management

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: “Game Changer”: Health Professionals’ Views on the Clinical Utility of Circulating Tumor DNA Testing in Hereditary Cancer Syndrome Management
  • Beteiligte: Shickh, Salma; Oldfield, Leslie E; Clausen, Marc; Mighton, Chloe; Sebastian, Agnes; Calvo, Alessia; Baxter, Nancy N; Dawson, Lesa; Penney, Lynette S; Foulkes, William; Basik, Mark; Sun, Sophie; Schrader, Kasmintan A; Regier, Dean A; Karsan, Aly; Pollett, Aaron; Pugh, Trevor J; Kim, Raymond H; Bombard, Yvonne; Pugh, Trevor J; Kim, Raymond H; Bombard, Yvonne; Aguilar-Mahecha, Adriana; Aronson, Melyssa; [...]
  • Erschienen: Oxford University Press (OUP), 2022
  • Erschienen in: The Oncologist
  • Sprache: Englisch
  • DOI: 10.1093/oncolo/oyac039
  • ISSN: 1083-7159; 1549-490X
  • Schlagwörter: Cancer Research ; Oncology
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:title>Abstract</jats:title> <jats:sec> <jats:title>Background</jats:title> <jats:p>We explored health professionals’ views on the utility of circulating tumor DNA (ctDNA) testing in hereditary cancer syndrome (HCS) management.</jats:p> </jats:sec> <jats:sec> <jats:title>Materials and Methods</jats:title> <jats:p>A qualitative interpretive description study was conducted, using semi-structured interviews with professionals across Canada. Thematic analysis employing constant comparison was used for analysis. 2 investigators coded each transcript. Differences were reconciled through discussion and the codebook was modified as new codes and themes emerged from the data.</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>Thirty-five professionals participated and included genetic counselors (n = 12), geneticists (n = 9), oncologists (n = 4), family doctors (n = 3), lab directors and scientists (n = 3), a health-system decision maker, a surgeon, a pathologist, and a nurse. Professionals described ctDNA as “transformative” and a “game-changer”. However, they were divided on its use in HCS management, with some being optimistic (optimists) while others were hesitant (pessimists). Differences were driven by views on 3 factors: (1) clinical utility, (2) ctDNA’s role in cancer screening, and (3) ctDNA’s invasiveness. Optimists anticipated ctDNA testing would have clinical utility for HCS patients, its role would be akin to a diagnostic test and would be less invasive than standard screening (eg imaging). Pessimistic participants felt ctDNA testing would add limited utility; it would effectively be another screening test in the pathway, likely triggering additional investigations downstream, thereby increasing invasiveness.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions</jats:title> <jats:p>Providers anticipated ctDNA testing will transform early cancer detection for HCS families. However, the contrasting positions on ctDNA’s role in the care pathway raise potential practice variations, highlighting a need to develop evidence to support clinical implementation and guidelines to standardize adoption.</jats:p> </jats:sec>
  • Zugangsstatus: Freier Zugang